Ribociclib

• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended
  2024-518811-20-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended
  2024-512925-95-00 Phase III 16 countries Pfizer Inc.
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended
  2022-502980-39-00 Phase III 13 countries F. Hoffmann-La Roche AG
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended
  2022-502231-19-00 Phase I/II 2 countries Pfizer Inc.
• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended
  2023-509408-13-00 Phase IV 10 countries Pfizer Inc.
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended
  2024-514891-41-00 Phase IV 5 countries Novartis Pharma AG
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended
  2023-504997-39-00 Phase III 8 countries AstraZeneca AB
• Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended
  2024-511934-11-00 Phase II 4 countries Novartis Pharma AG
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended
  2024-515769-32-00 Phase III 1 country WSG Westdeutsche Studiengruppe GmbH
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended
  2023-510357-42-00 Phase III 10 countries Novartis Pharma AG
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended
  2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
• An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are c… Ended
  2024-511125-61-00 Phase I/II 2 countries Novartis Pharma AG
• A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended
  2023-509511-84-00 Phase I/II 2 countries Novartis Pharma AG
• Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in… Ended
  2022-501527-24-00 Phase I/II 1 country Centre Antoine Lacassagne
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 Phase I (FiH) 4 countries Blueprint Medicines Corp.
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended
  2022-502372-22-01 Phase II 1 country Unicancer
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year… Ended
  2024-512095-35-00 Phase I/II 7 countries Novartis Pharma AG
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 Phase III 2 countries Solti Group

Showing 25–44 of 44 trials